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Advanced Glycation End products (AGEs) are the products of nonenzymatic glycation and oxida-
tion of proteins and lipids. Formation of AGEs is increased in response to hyperglycaemia, reactive
oxygen species and ageing. AGEs are proinflammatory and can modify the extracellular matrix.
RAGE (Receptor for Advanced Glycation End Products) mediates some of the effects of AGEs.
Methods: Formalin-fixed lung tissue from patients who had lobectomy for bronchial carcinoma
was used to investigate the presence of AGEs and RAGE. Subjects were divided into those with
COPD and controls. Immunostaining for AGEs and RAGE was performed and the intensity of stain-
ing measured.
Results: Subjects with COPD and controls were similar in age and smoking history but FEV1% pre-
dicted was lower for COPD than controls. Intensity of staining for AGEs was greater in the airways
(pZ 0.025) and alveolar walls (pZ 0.004) in COPD. Intensity of staining for RAGE was also signif-
icantly increased in alveolar walls (pZ 0.03) but not the airways. FEV1% predictedwas correlated
with the intensity of staining for AGEs in the airways and alveoli.
Conclusions: The increased staining for both AGEs and RAGE in COPD lung raises the possibility
that the RAGEeAGEs interaction may have a role in the pathogenesis of COPD.
ª 2010 Elsevier Ltd. All rights reserved.Introduction
The advanced glycosylation process is a spontaneous inter-
action between reducing sugars and a wide variety of
proteins and lipids that induces a post-translational02447838; fax: þ64 93737556.
.nz (L. Wu).
0 Elsevier Ltd. All rights reservedmodification of the protein or lipid and may increase the
stiffness of matrix proteins. Advanced Glycation End prod-
ucts (AGEs) are the products of this nonenzymatic glycation
and oxidation of proteins and lipids.1,2 Under normally
physiological conditions AGEs are formed at a very slow but.
330 L. Wu et al.steady rate and accumulated with ageing. Their production,
however, is accelerated in inflammatory conditions such as
hyperglycaemia and oxidative stress.3 Proteins with low
turn-over rateswithin the extracellularmatrix (e.g. collagen
and elastin) are particularly prone to AGEs modification.
In diabetic patients, evidence has been found indicating
that neurofilaments (a very stable protein) cross-link with
AGEs and accumulate in diabetic neuropathy.4 The accelera-
tion of the formation of AGEs has been also shown to
contribute to the development of diabetic complications such
as retinopathy and vascular disease.5 AGEs have also been
found toaccumulate in thebrain andare thought toplay a role
in the development and progression of Alzheimer disease
throughcellular responses toROS(reactiveoxygenspecies).6,7
Ageing and smoking are the two major risk factors of
chronic obstructive pulmonary disease (COPD).8 However,
how these two factors contribute to the development of
COPD is still unclear. Ageing and smokingmay also contribute
to the acceleration of the formation of AGEs.9 AGEs are one
of a number of structurally similar ligands for the receptor
RAGE.10,11 Binding of AGEs to RAGE leads to activation of NF-
kB (nuclear factor-KappaB) and promotes inflammation.12
AGEs may therefore play a role in the development of
COPD possibly through inflammation.
The receptor for advanced glycation end products
(RAGE) is a member of the immunoglobin (Ig) superfamily.11
RAGE is a single membrane spanning receptor, consisting of
a very short cytosolic domain and a large extracellular
region containing three Ig-like domains.13 RAGE can bind
with a myriad of ligands including AGEs, amphoterin, and
S100/calgranulin.14
RAGE is expressed at low levels in normal tissues and in
blood vessels but becomes up-regulated at sites where its
ligands accumulate. Recently, Demling and colleagues
confirmed that RAGE is abundantly expressed in normal
lung tissue.15 By analyzing alveolar epithelial type II cells
(AT II cells) transdifferentiating in vitro into AT I cells, they
identified RAGE as a specific “differentiation marker” of
human AT I cells. RAGE was also found to be expressed in
endothelia and alveolar macrophages, other than type II
alveolar pneumocytes. They also showed in vitro that RAGE
promotes the adherence of epithelial cells to collagen and
induces spreading.15
Based on previous published work from other groups, we
were interested to knowwhether the RAGEeAGEs interaction
might represent a novel pathway promoting inflammation in
lung disease, and particularly in Chronic Obstructive Pulmo-
nary Disease (COPD). COPD is characterised by poorly revers-
ible airflow obstruction that is usually, but not invariably, due
to cigarette smoking. The pathological changes in COPD are
inflammation of the peripheral airways and destruction of the
lung parenchyma (emphysema). The mechanism of develop-
ment and progression of COPD, however, is still not clear.
Chronic smoking andpollutant exposure, that cause a series of
inflammatory stresses, are believed to play key roles in the
pathogenesis of COPD.16 To date the role of AGEs and RAGE
have not been investigated in COPD.17
Aim of this study
To investigate the presence of RAGE and its ligand AGEs in
lung tissue from control subjects and patients with COPD.Methods
Subjects
Blocks of archival, formalin-fixed lung tissue were used for
this study. Blocks were from patients who had had one or
more lobes of the lung resected for bronchial carcinoma. The
specimenswere identified through the computerized records
of the Department of Pathology, GreenLane Hospital. The
operations were performed between January 1992 and
September 1996. All of the blocks used were from sites
remote from the bronchial carcinoma. Further information,
including smoking history, past medical history, medication,
and preoperative lung function, were obtained from the
patient’s hospital notes. Patients were excluded if they had
a history of asthma. Patientswere classified as having COPD if
their FEV1 was <80% predicted and the ratio of FEV1 to FVC
was <70%. This is equivalent to GOLD Stage 2e4. Patients
with FEV1>80%predictedandFEV1/FVC>70%were served as
controls. Both groups were non-diabetic. (see Table 1 for
summary of patient groups).
Immunostaining methods
Sections were cut at 5 mm on a microtome and mounted on
poly-L-lysineetreatedmicroscope slides. Immediately before
staining, the slides were warmed to 37 C in an incubator for
at least 1 h. Sections were then deparaffinized in xylene and
rehydrated in a grading series of alcohol dilutions and 0.01 M
phosphate-buffered saline (PBS) for 5 min. Sections were
then treated with DAKO (R) Target Retrieval Solution (Dako,
Glostrup Denmark) for 30 min at 98 C to enhance antibody
labeling. After 3 washes of 5 min in PBS, sections were incu-
bated overnight with mouse anti-human AGEs (clone 6D12,
1:200, Cosmo Bio, Japan) or goat anti-human RAGE (Biode-
sign, 1:200, Meridian Life Science, ME USA) antibody at 4 C.
After a further three washes in PBS for 5 min each, the
secondary antibody (Jackson immunoresearch, USA), goat
anti-mouse biotin conjugated, was applied to the sections
overnight at 4 C for AGE staining. Sections were washed in
PBS three times for 5 min then treated with ABC (Vectastain
Elite ABC kit; Vector Laboratories, Burlingame, CA USA)
solution for 2 h at room temperature and the reaction visu-
alized with diaminobenzidine (Sigma, USA) and H2O2. For
RAGE staining, rabbit anti-goat IgG peroxidase conjugated
(1:1500, Biodesign), was applied as secondary antibody to the
sections for 4 h at room temperature. The reaction was
visualized with 0.05% diaminobenzidine (Sigma, USA) 0.01%
H2O2. Negative control sections were incubated with PBS in
the absence of the primary antibody. Sections of mouse brain
were used as a negative control.
Staining quantification
Immuno stained sections were observed on a Nikon micro-
scope (Nikon, Tokyo, Japan). Digital images were taken
using a Nikon digital microscope camera system (Nikon,
Tokyo, Japan). For all quantification processes of staining
the observer was blind to COPD status of each subject.
The intensity of staining for AGEs and RAGE was
measured using Image J software (National Institutes of
Table 1 Summary of the two patient groups.
COPD mean (SD) Non COPD mean (SD) P-value
Age 64.8 (1.7) 62.7 (2.0) Not significant
Smoking pack yrs 43.4 (4.8) 44.1 (4.9) Not significant
FEV1% of predicted 62.7 (1.8) 94.1 (2.8) P < 0.01
FVC % of predicted 80.3 (2.4) 92.6 (3.7) P < 0.05
FEV1/FVC% 58.0 (1.6) 77.4 (1.4) P < 0.01
Number of subjects 20 (13M/7F) 18 (11M/7F) Not significant
The study was approved by the North Health Ethics Committee, Auckland, New Zealand.
AGEs and RAGE in COPD 331Health, Bethesda, Maryland, USA). All small airways
(bronchioles without cartilage, normally 3e6 for each
section) were photographed digitally. Intensities were
determined for successive fields across the section. Back-
ground staining intensities were determined for adjacent or
close by control sections (with the primary antibody
omitted.) and subtracted from intensities determined for
the antibody-stained sections. For each positive stained
region, 10 measuring spots were sampled randomly and an
average intensity  SD was calculated.
The number of cells positive for AGEs and RAGE was
counted manually. Briefly, the middle field (20) of each
section was chosen for analysis. The total number of cells and
the number of positive cells were counted in successive fields
at a magnification of 400, starting at the centre of the top
edge of the section and proceeding straight down to the
bottom of the section until a vertical column had been coun-
ted. 10e15 successive fields for each section were counted.
Statistics analysis
All the data were analysed using a SAS system software
(version: enterprise 9.1) package.
All P values of <0.05 are taken to be significant.
Student’s t-test was used to compare the difference
between two groups and Spearman Correlation Coefficients
test was used for the correlation between the staining
intensity and FEV1% of predicted value.
Results
The characteristics of the subjects are shown in Table 1.
Subjects with COPDwere similar to the controls with respect
to age, gender and smoking history but, had lower lung
function. FEV1 was 62  1.8% of predicted in the subjects
with COPD compared with 94  2.8% for the controls.
AGEs staining
Positive staining of AGEs was mainly confined to the cell
membrane of the single layer of epithelium of alveolar walls.
In the small airway areas, positive staining of AGEswas found
both on the surface and in the cytoplasm of goblet cells and
epithelial cells. The cilia of small airways also stained posi-
tively in most sections. Positive staining was also occasion-
ally found in the stroma of small airways and in the
pulmonary macrophages in the lumen of airways (Fig. 1).
While the number of cells positive for AGEs was not
significantly different between the COPD group and non-COPD controls, the intensity of the positive staining was
significantly stronger in the COPD group than in the non-
COPD control group (p Z 0.004) (Fig. 2). Furthermore the
mean intensity of AGEs staining around the small airway
areas (bronchiolesenoncartilaginous conducting airways)
was stronger in the COPD group than in the non-COPD
control group (p Z 0.025) (Fig. 3).
RAGE staining
The positive staining of RAGE was mainly located on the cell
membrane of alveolar walls. Positive staining of RAGE was
also observed in the cytoplasm. (Fig. 4).
The intensity of staining for RAGE was stronger in the
COPD group than in non-COPD control group. (p Z 0.027)
(Fig. 5). The mean staining intensity for RAGE in the small
airways of the COPD group was, however, not significantly
different to that of the non-COPD control group. (pZ 0.26)
(Fig. 6). However, patients with low FEV1% of predicted
values had a stronger intensity of RAGE staining than
subjects with higher FEV1% of predicted values (pZ 0.0069)
and the intensity of staining was strongly associated with
FEV1% of predicted alone (Fig. 7).
Discussion
In this study, subjects from two groups (COPD and non-
COPD) were well controlled with no significant difference in
age, gender, smoking history and medical histories; both
groups were non-diabetic patients with bronchial carci-
noma. The only major uncontrolled factor between these
two groups was their lung function. Subjects from the COPD
group had significantly lower ratios in FEV1% of predicted
value and FEV1/FVC which together represent a poorer
airflow in the lungs.
We found that in the COPD group, subjects had a signif-
icantly higher staining intensity for AGEs in lung paren-
chyma and in the small airways than in the non-COPD
control group. COPD subjects also had a significantly higher
staining intensity for RAGE in lung parenchyma than in the
non-COPD control group, and that the intensity of RAGE
staining was strongly correlated with the patients’ lung
function measured by FEV1% of predicted. Together these
results suggest that the AGEseRAGE interaction may be
more common and more intense in the lungs of COPD
patients and around small airways than in the non-COPD
controls.
Our findings are consistent with the results from a recent
study by Ferhani and colleagues.18 In that study, they found
Figure 1 A: AGEs staining in COPD bronchioles. In the small airways, the positive staining of AGEs was found on the surface
(Arrow a) and in the cytoplasm (Arrow b) of epithelium cells. The cilia (Arrow c) of small airways were also stained positively in
most sections. Positive staining was also occasionally found in the stroma (Arrow d) of bronchioles and in the pulmonary macro-
phages in lumen of airways. B: AGEs staining in non-COPD bronchioles. While the positive staining of AGEs had a similar pattern to
COPD bronchioles the intensity of staining was significantly weaker (Arrow a: positive staining on the surface of epithelium cells.
Arrow b: positive staining in the cytoplasm. Arrow c: positive staining of the cilia of small airways.). C: AGEs staining in alveolar
walls of COPD. The positive staining of AGEs was seen in the pulmonary macrophages in lumen of the alveoli (Arrows a and c). The
positive staining of AGEs was mainly confined to the cell membrane of the single layer of squamous epithelium of alveolar walls
(Arrow b). D: AGEs staining in alveolar walls of non-COPD. Positive staining was seen in the epithelium cells of alveolar walls (Arrows
a and b). Positive staining was also seen in the pulmonary macrophages in lumen of the alveoli (Arrow c). The scale barZ 5um (A,
B, C and D).
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Figure 2 The intensity of the positive staining was signifi-
cantly stronger in the COPD group than in non-COPD control
group (*pZ 0.004). Bars above and below the means show SD.
AGEs and RAGE in COPD 333that RAGE was overexpressed in the airway epithelium and
smooth muscle of patients with COPD and RAGE colocalized
with HMGB1 (High-mobility group box 1). They also found
that smokers with COPD had higher levels of HMGB1 in their
BAL fluid than did smokers without COPD, or never-smoker
healthy individuals. The authors suggest that the existence
of an autocrine/paracrine loop in which binding of HMGB1 to
IL-1b, and possibly to RAGE and potentially other HMGB1
receptors, amplifies inflammatory and remodelling signals
that are involved in COPD pathogenesis. In an animal study,19
the authors reported that feeding rats with AGEs-enriched
foods resulted in an increased level of AGEs in lung tissue
after 2 wk of feeding. Furthermore, the mRNA expression of
HMGB1 was also increased in response to the AGEs-rich foods
but not in response to the ageing associated AGEsCOPD NON-COPD
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Figure 3 In bronchioles, the intensity of positive staining of
AGEs was stronger in the COPD group than in non-COPD control
group (*pZ 0.025). Bars above and below the means show SD.modifications in vivo. Based on these findings, it is very
possible that the elevated AGEs levels in lung tissues from
COPD patients may cause the increase of HMGB1 expression.
Advanced Glycation End products (AGEs) are the result of
a chain of chemical reactions following an initial glycation
reaction.AGEs are a heterogenous class of compounds formed
bydiverse stimuli, includinghyperglycaemia, oxidative stress,
inflammation, renal failure, and innate ageing.5 There is
considerable evidence of increased oxidative stress in the
lungs of patients with COPD with a number of studies doc-
umenting increased expression of markers of oxidative stress
in the lungs of patients with COPD, compared to healthy
subjects or smokers with a similar smoking history who have
not developed COPD.18 Since a possible consequence of the
cumulated chronic oxidative stress in COPD patients is
increased AGEs, the higher staining intensity for AGEs we
observed is consistent with findings in other studies. In addi-
tion, thepossibility ofpoorclearanceofAGEs inCOPDpatients
may also contribute to the observed increase in AGEs. In dia-
betics, it has been found that suffering from increase AGE
production, subsequent kidney damage (by AGE production in
the glomerulus) reduces the subsequent urinary clearance of
AGEs, forming a positive feedback loop and further increasing
the rate of damage.20
RAGE (receptor for advanced glycation end products)
was initially isolated from endothelial cells of bovine
lung.11 RAGE transgenic and knockout mice have provided
functional genomic models to help identify the roles of
RAGE. It was found that transgenic mice with high levels of
expression of full length RAGE developed the diabetic
pathogenic changes and were susceptible to the develop-
ment of diabetic nephropathy.21 The RAGE knockout mice
model also demonstrates that RAGE is associated with
atherosclerosis.22 In homozygous RAGE null mice, a signifi-
cant decrease in neointimal expansion after arterial injury
and decreased smooth muscle cell proliferation, migration,
and expression of extracellular matrix proteins was
observed. In a sepsis knockout mouse model,23 the deletion
of RAGE provides protection from the lethal effects of
septic shock caused by cecal ligation and puncture. For
hemorrhagic shock, the RAGE knockout mice model24
showed that activation of RAGE-dependent signaling is
a key factor leading to gut mucosal barrier dysfunction
after hemorrhagic shock and resuscitation.
In most AGEs-RAGE related diseases, RAGE expression is
up-regulated in response to the disease. For example, in the
Alzheimer’s disease brains, RAGE is up-regulated and serves
to activate microglia as well as mediate amyloid-b transport
across the bloodebrain barrier.25 In diabetic vasculature
that is prone to atherosclerosis, RAGE expression is up-
regulated and together with its ligands AGEs and S100/
calgranulins, initiates proinflammatory signaling that exac-
erbates plaque formation.26 In contrast, in both mouse
models and human idiopathic pulmonary fibrosis (IPF) lungs,
RAGE and sRAGE expression is significantly down regulated
after profibrotic pulmonary injury. COPD does however have
an opposing mechanism of action to that of IPF. IPF is asso-
ciatedwith overexpression of collagen and elastin in the lung
tissue while COPD is believed to be associated with the
decrease of collagen and elastin in lung. While AGEs and
RAGE were found to be decreased in the lung tissues with
IPF27,28 AGEs and RAGE staining intensity were both found to
Figure 4 A: RAGE staining in COPD alveolar walls. The positive staining of RAGE was mainly located to the cell membrane of the
epithelial cells of alveolar walls (Arrows a and b). Positive staining of RAGE was also observed in the cytoplasm of epithelial cells
(Arrow c). B: RAGE staining in non-COPD alveolar walls. The positive staining of RAGE had a similar pattern to that seen in COPD
sections, however, the staining intensity was much lower than in the COPD alveolar walls (Arrow a and c). Positive staining was also
found in the cytoplasm (Arrow b). The scale bar Z 5um (A and B).
334 L. Wu et al.be significantly higher in the non-diabetic COPD group
compared to the non-COPD control group in our study.
The role of RAGE and AGEs in maintaining and amplifying
inflammation has been documented only recently. RAGE-
mediated tissue degradation has been implicated in the
chronic inflammatory pathogenesis in many organs. In lung,
the RAGEeAGEs interaction has been associated with
a number of lung diseases including acute lung injury,29
cystic fibrosis,30 common interstitial diseases and post-COPD NON-COPD
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Figure 5 The intensity of staining for RAGE in alveolar walls
was stronger in the COPD group than in non-COPD control group
(*p Z 0.027). Bars above and below the means show SD.obstructive pneumonia.31 In a recent review by Schmidt and
colleagues, authors suggest that the RAGEeAGEs interaction
may not play a causative role or initiating factor in these
lung diseases, but rather acts as a mediator of amplification
of chronic cellular activation such as cellular dysfunction
and tissue destruction.3 It is possible, the AGEs eRAGE
interaction also accelerates the processes of COPD by
promoting inflammatory and perhaps other pathways.RAGE mean staining intensity in bronchioles
COPD NON-COPD
0
50
100
150
200
p=0.26
R
A
G
E
 
a
i
r
w
a
y
 
m
e
a
n
 
i
n
t
e
n
s
i
t
y
Figure 6 The mean staining intensity for RAGE in the bron-
chioles of the COPD group was not significantly different to
that of the non-COPD control group (pZ 0.26). Bars above and
below the means show SD.
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Figure 7 Patients with the lower FEV1% of predicted value
had a stronger intensity of RAGE staining in alveolar walls than
subjects with higher FEV1% of predicted values (*p Z 0.0069).
AGEs and RAGE in COPD 335The AGEs and RAGE interaction can increase intracellular
oxidative stress by activating NADPH-oxidase (Nicotinamide
adenine dinucleotide phosphate), a central player in the
production of superoxide radicals.32 Recently it has been
reported that NADPH-oxidase enhances susceptibility to the
proinflammatory effects leading to airspace enlargement
and alveolar damage.33
Other components of the signal transduction pathways
of AGEs downstream of RAGE are p21ras and ERK1/2.34 The
MAPKs (including Erk1/2) have been reported to mediate
transcription of proteases and cytokines in response to
a variety of stimuli. Smoking or other components of ciga-
rettes indeed activate the MAPK-Erk1/2 pathway in fibro-
blasts, smooth muscle cells, pulmonary epithelial cells, and
bronchoalveolar cells which may contribute the develop-
ment of COPD.35
The AGEseRAGE interaction can also activate signal
transduction pathways that include transcription factors
such as NF-kB36,37 that bind to the promoter sites of many
proinflammatory cytokines such as IL-1, IL-6, TNF-a and the
inducible nitric oxide synthase.38 Cytokines or other
proinflammatory stimuli can themselves activate NF-kB,
and this turn induces RAGE expression and subsequent
RAGE-mediated perpetuated NF-kB activation creating
a positive autoregulatory loop.39,40
It is therefore quite possible that the increase in
AGEseRAGE interactions in COPD lung amplify the inflam-
matory response through the activation of NF-kB.
Currently, increasing evidence suggests that COPD is also
involved with systemic inflammation. Serum TNF-a, IL-6
and TIMP-1 concentrations are significantly higher in
patients with stable COPD than in control patients.41,42 The
AGEseRAGE interaction may also contribute to this increase
in these cytokines.
Conclusions
The staining intensities of AGEs and RAGE were significantly
higher in our non-diabetic COPD group than our non-COPD
control group. The AGEseRAGE interaction may contributeto the development of COPD in a number of ways including
airway and alveolar destruction, cytokine production and
inflammation. Further studies are now required to deter-
mine the precise role of the AGEseRAGE interaction and to
investigate whether the blockade of this receptoreligand
interaction slows the progression of COPD development.
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